New England Journal of Medicine· 2026Q1
Erişkin Ph-Pozitif ALL İçin Ponatinib–Blinatumomab veya İmatinib–Kemoterapi
Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL
- 1atıf
- Q1SCImago
- 2026yıl
Kısa özet
Ön tedavi olarak ponatinib ve blinatumomab kombinasyonu, yetişkin Philadelphia kromozomu pozitif akut lenfoblastik lösemi (Ph-pozitif ALL) hastalarında imatinib artı kemoterapiye kıyasla anlamlı derecede daha yüksek %86'ya karşılık %67 oranında 24 aylık hastalıksız sağkalım sağlamıştır.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- Ponatinib artı blinatumomab, imatinib artı kemoterapiye kıyasla %86 oranında 24 aylık hastalıksız sağkalım sağlamıştır (%67'ye karşı) (P<0.001).
- Ponatinib-blinatumomab alan hastaların %94'ünde tam hematolojik yanıt elde edilirken, imatinib-kemoterapi alanlarda bu oran %79'dur.
- Konsolidasyon sonrası moleküler yanıt oranları ponatinib-blinatumomab için %71, imatinib-kemoterapi için ise %49 olmuştur.
- Bu ön tedavi denemesinde kemoterapi içermeyen hedefe yönelik ve immünoterapötik yaklaşımın üstün olduğu bulunmuştur.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
BACKGROUND: The outcome of Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL) has greatly improved with the use of tyrosine kinase inhibitors and immunotherapy. METHODS: In this trial, we randomly assigned adult patients with Ph-positive ALL in a 2:1 ratio to receive ponatinib plus blinatumomab (intervention group) or imatinib plus chemotherapy (control group) as frontline treatment. A crossover to the intervention group was allowed for patients with persistence or reappearance of measurable residual disease in the control group. The primary end point was event-free survival. RESULTS: A total of 236 patients underwent randomization: 158 to the intervention group and 78 to the control group. The median age of the patients was 55 years (range, 24 to 82). At a median follow-up of 23.7 months, the estimated 24-month event-free survival was 86% in the intervention group and 67% in the control group (P<0.001). Survival with no measurable residual disease was 68% and 42%, respectively. At the end of induction, a complete hematologic response was observed in 94% of the patients in the intervention group and in 79% of those in the control group. After blinatumomab consolidation, a molecular response was observed in 71% and 49% of the patients, respectively. After crossover to the intervention group, 20 of 31 patients (64%) had a molecular response. Overall survival was 90% in the intervention group and 85% in the control group. The cumulative incidence of relapse was 5% and 13%, respectively. As of this report, only 19% of the patients in the intervention group had undergone hematopoietic stem-cell transplantation after having had a first complete hematologic response. CONCLUSIONS: In this phase 3 trial, a frontline chemotherapy-free targeted and immunotherapeutic approach was superior to the use of imatinib and chemotherapy. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA ALL2820 ClinicalTrials.gov number, NCT04722848.).
Yazarların özeti; kaynağından alınmıştır. New England Journal of Medicine, 2026 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Halk Sağlığı, Çevre ve İş Sağlığı
Public Health, Environmental and Occupational HealthMedicine